Cardiac Biomarker Testing Market is Anticipated to Grow at a CAGR of 7.76% and is also Expected to Reach USD 5.07 Billion by 2026, Analyzes DelveInsight

Cardiac Biomarker Testing Market is Anticipated to Grow at a CAGR of 7.76% and is also Expected to Reach USD 5.07 Billion by 2026, Analyzes DelveInsight

PR Newswire

LAS VEGAS, Dec. 16, 2021

The Cardiac Biomarker Testing market is anticipated to upsurge due to the rising burden of cardiology disease, the growing need for early diseases diagnosis, the introduction of technologically advanced products, and increasing cost of healthcare expenditure are expected to help the market and the patients in their treatment which will drive the market growth.

LAS VEGAS, Dec. 16, 2021 /PRNewswire/ -- DelveInsight's Cardiac Biomarker Testing Market Insights and Forecast report provides the current and forecast Cardiac Biomarker Testing Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Cardiac Biomarker Testing Market. 

DelveInsight_Logo

Some of the salient features from the Cardiac Biomarker Testing Market report: 

To pick on the latest highlights related to Cardiac Biomarker Testing, get the snapshot of the key highlights entailed in the Cardiac Biomarker Testing Market report.

Cardiac Biomarker Testing Overview 

Cardiac Biomarkers are elements that are released into the blood when the heart is damaged or stressed and estimation of these biomarkers might be helpful in diagnoses of conditions associated with insufficient blood flow to the heart like acute coronary syndrome (ACS) and cardiac ischemia. These tests can also be used in determining a person's risk of having these conditions or to aid in monitoring and managing someone with suspected ACS and cardiac ischemia. These are vital in various cardiovascular conditions such as Congestive heart failure (CHF), ischemic heart diseases (IHD), diabetic cardiomyopathy (DCM), acute coronary syndromes (ACS), and acute myocardial infarction (AMI).

Several Cardiac Biomarkers have been used in the diagnosis and management of cardiovascular (CV) diseases. Cardiac Biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac Biomarkers are also a powerful tool for triaging.

Interested in knowing about Cardiac Biomarker Testing Market growth by 2026? Click to get a snapshot of Cardiac Biomarker Testing Market Analysis

Cardiac Biomarker Testing Market Insight 

Geographically, the global Cardiac Biomarker Testing market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share North America currently leads the global market and is expected that it will remain constant during the forecast period. However, the supremacy of North America will be evidently challenged by the European market. This domination is due to the growing demand for testing owing to the rising prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities, and demand for advanced technologies in Cardiac Biomarker Testing in the region.

According to the analysis, in the biomarker type segment of the Cardiac Biomarker testing devices market, the troponin category of Cardiac Biomarkers is predicted to account for the significant market revenue share. This can be ascribed to the fact that it is considered the best Cardiac Biomarker among all other Cardiac Biomarker types. This protein is by far the most commonly used biomarker and has the highest known sensitivity. Other biomarkers such as CK, CK-MB, and myoglobin have limited use, therefore boosting the demand for troponin and further enhancing the Cardiac Biomarker Testing market.

To know more why North America is the leader in market growth for the Cardiac Biomarker Testing Market, get a snapshot of the report Cardiac Biomarker Testing Market

Cardiac Biomarker Testing Market Dynamics

The increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers, will lead to rising demand for Cardiac Biomarker Testing. There are approximately 200,000 coronary artery bypass graft surgeries that take place each year in the US and are the most commonly performed cardiac procedure. The diagnosis is required for better surgery results, which is boosting the demand for the advanced Cardiac Biomarker Testing market.

The demand for Cardiac Biomarker Testing is primarily affected by the outbreak of the COVID- 19 pandemic. The government imposed lockdowns to curb the spread of the virus leading to restrictions in movement and a decrease in regular check-ups. Owing to the COVID-19 pandemic situation, various forms of elective procedures were temporarily stopped in contrast to the COVID-19 affected patients that were given utmost priority. This lead to a decrease in the demand for Cardiac Biomarker Testing. 

To get a deeper understanding of the driving factors related to the Cardiac Biomarker Testing Market, find a snapshot of the Cardiac Biomarker Testing Market Dynamics.

Scope of the Cardiac Biomarker Testing Market Report

Study Period: 2018-2026

Key Companies: Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation/Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex

Cardiac Biomarker Testing Market Segmentation

By Product 

By Biomarker Type

By Application

By End-User

By Geography

Delveinsight Analysis: The Cardiac Biomarker Testing market is expected to grow at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach 5.07 billion by 2026.

Table of Contents 

1

Cardiac Biomarker Testing Market Report Introduction

2

Cardiac Biomarker Testing Market Executive summary

3

Regulatory and Patent Analysis

4

Cardiac Biomarker Testing Market Key factors Analysis

5

Cardiac Biomarker Testing  Porter's Five Forces Analysis

6

COVID-19 Impact Analysis on Cardiac Biomarker Testing Market

7

Cardiac Biomarker Testing Market Layout

8

Cardiac Biomarker Testing  Global Company Share Analysis – Key 3-5 Companies

9

Cardiac Biomarker Testing Market Company and Product Profiles


9.1 Beckman Coulter, Inc

9.2 Siemens Healthcare GmbH

9.3 Abbott

9.4 bioMérieux SA

9.5 F. Hoffmann-La Roche Ltd

9.6 Thermo Fischer Scientific Inc

9.7 Bio-Rad Laboratories Inc

9.8 Eurolyser Diagnostica GmbH

9.9 Diagnostic Automation / Cortez Diagnostics, Inc

9.10 Randox Laboratories Ltd

9.11 Tosoh Corporation

9.12 DIALAB GmbH

9.13 CardioGenics Holdings Inc

9.14 Lepu Medical Technology (Beijing) Co. Ltd.

9.15 Biosynex 

10

Project Approach

11

KOL Views

12

About DelveInsight

13

Disclaimer & Contact Us

Explore more about what the report has to offer @ Cardiac Biomarker Testing Market Outlook

Understand the Competition, Risk Assessment, and effective Research and Development approach to take value-based decisions.

Related Reports

Implantable Cardiac monitors Market 

"DelveInsight's 'Implantable Cardiac monitors (ICM) - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Implantable Cardiac monitors (ICM) and the historical and forecasted Implantable Cardiac monitors (ICM) market trends, market drivers & barriers, unmet needs, and key companies involved such as Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Medtronic plc, Angel Medical Systems Inc, and others.

Cardiac Restoration Systems Market

"DelveInsight's 'Cardiac Restoration Systems - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Restoration Systems and the historical and forecasted Cardiac Restoration Systems market trends, market drivers & barriers, unmet needs, and key companies involved such as Abbott, BioVentrix, CryoLife, Inc, Edwards Lifesciences Corporation, NeoChord, Inc., XELTIS, and others.

Cardiac Ablation Devices

Global Cardiac Ablation Devices Market was valued at USD 2.00 billion in 2020, growing at a CAGR of 12.78% during the forecast period from 2021 to 2026, to reach USD 4.12 billion by 2026. The report delivers an in-depth understanding of Cardiac Ablation Devices and the historical and forecasted Cardiac Ablation Devices market trends, market drivers & barriers, unmet needs, and key companies involved such as Abbott Laboratories, Boston Scientific Corporation, Avanos Medical, Auris Health, Olympus, CONMED Corporation, ERBE ELEKTROMEDIZIN GMBH, AngioDynamics, Medtronic Inc, Teleflex Incorporated, St. Jude Medical Inc, and many others.

Cardiac Valvulotome Market

"DelveInsight's 'Cardiac Valvulotome - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Valvulotome and the historical and forecasted Cardiac Valvulotome market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Braun Melsungen AG, LeMaitre Vascular, Inc., Andramed GmbH,BD., InvaMed, Koven Technology Canada Inc, and others.

Cardiac Resynchronization Therapy Market

"DelveInsight's 'Cardiac Resynchronization Therapy - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Resynchronization Therapy and the historical and forecasted Cardiac Resynchronization Therapy market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems, Abbott, and others.

Cardiac Restoration Systems Market 

"DelveInsight's 'Cardiac Restoration Systems - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Restoration Systems and the historical and forecasted Cardiac Restoration Systems market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Abbott, BioVentrix,CryoLife, Edwards Lifesciences Corporation,NeoChord, XELTIS, and others.

Cardiac Output Monitors Market 

"DelveInsight's 'Cardiac Output Monitors - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Output Monitors and the historical and forecasted Cardiac Output Monitors market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Osypka Medical GmbH, CNSystems Medizintechnik GmbH., Uscom,Deltex Medical Limited, Edward Lifesciences Corporation, ICU Medical, Inc., LiDCO, Baxter., Getinge AB., GE Healthcare (GENERAL ELECTRIC COMPANY), Biotronik, and others.

Cardiac Monitoring Devices Market

Global Cardiac Monitoring Devices Market report delivers an in-depth understanding of Cardiac Monitoring Devices and the historical and forecasted Cardiac Monitoring Devices market trends, market drivers & barriers, unmet needs, and key companies involved such as Medtronic, Boston Scientific, Abbott Laboratories, GE Healthcare, BIOTRONIK, and Koninklijke Philips, Asahi Kasei Corporation, MicroPort Scientific Corporation, Hill-Rom Holdings, Nihon Kohden, SCHILLER AG, BioTelemetry, BPL Medical Technologies, ACS Diagnostics, and others.

Cardiac Assist Devices Market 

Global Cardiac Assist Devices Market was valued at USD 2.55 billion in 2020, growing at a CAGR of 13.70% during the forecast period from 2021 to 2026, to reach USD 5.50 billion by 2026. The report delivers an in-depth understanding of Global Cardiac Assist Devices and the historical and forecasted Global Cardiac Assist Devices market trends, market drivers & barriers, unmet needs, and key companies involved such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, NovaPump GmbH, Getinge AB Balton Ltd, Meril Life Sciences Pvt. Ltd, Thoratec Corporation, and others.

3D Cardiac Mapping System Market 

"DelveInsight's '3D Cardiac Mapping System - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of 3D Cardiac Mapping System and the historical and forecasted 3D Cardiac Mapping System market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Biosense Webster, (Jhonson & Jhonson), Boston Scientific Corporation, Abbott, Kardium, Medtronic, Catheter Robotics, Inc, Lepu Medical, EP Solutions SA, and others.

Browse Through Our Blog Posts

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg  

Voltar noticias em Inglês